Every 8-K that PAVmed Inc. Series Z Warrant (PAVMZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PAVMZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVMZ filings page.
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics, completed an underwritten public offering of 28,750,000 shares of Lucid Diagnostics common stock at $1.00 per share, including full exercise of a 3,750,000-share underwriter option. After underwriting discounts and estimated offering expenses, the transaction is expected to generate approximately $26.9 million in net proceeds. Lucid Diagnostics intends to use the proceeds for working capital and general corporate purposes.
The filing is a straightforward capital raise by a subsidiary rather than PAVmed directly and provides a liquidity infusion for Lucid Diagnostics to support operations or near-term needs. No additional financial results, changes in ownership percentages, or specific allocations of the proceeds were disclosed in the text provided.
PAVmed Inc. furnished a Form 8-K dated August 14, 2025 reporting that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and providing a business update. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states the furnished information shall not be deemed "filed" under the Exchange Act nor incorporated by reference except as expressly stated. The report is signed by Dennis McGrath, President and Chief Financial Officer.